151 related articles for article (PubMed ID: 33398412)
21. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of
Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
[TBL] [Abstract][Full Text] [Related]
23. Intra-individual dynamic comparison of
Piron S; Verhoeven J; Descamps B; Kersemans K; De Man K; Van Laeken N; Pieters L; Vral A; Vanhove C; De Vos F
Sci Rep; 2020 Dec; 10(1):21068. PubMed ID: 33273603
[TBL] [Abstract][Full Text] [Related]
24. Intraindividual Comparison of
Dietlein F; Kobe C; Hohberg M; Zlatopolskiy BD; Krapf P; Endepols H; Täger P; Hammes J; Heidenreich A; Persigehl T; Neumaier B; Drzezga A; Dietlein M
J Nucl Med; 2020 May; 61(5):729-734. PubMed ID: 31628219
[No Abstract] [Full Text] [Related]
25. Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?
Leitsmann C; Thelen P; Schmid M; Meller J; Sahlmann CO; Meller B; Trojan L; Strauss A
Int Braz J Urol; 2019; 45(3):459-467. PubMed ID: 30901173
[TBL] [Abstract][Full Text] [Related]
26. Prognostic implications of dual tracer PET/CT: PSMA ligand and [
Michalski K; Ruf J; Goetz C; Seitz AK; Buck AK; Lapa C; Hartrampf PE
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2024-2030. PubMed ID: 33336265
[TBL] [Abstract][Full Text] [Related]
27.
Mesci A; Ahmadi E; Ali A; Gouran-Savadkoohi M; Evelyn Tsakiridis E; Biziotis OD; Chow T; Kapoor A; Sur M; Steinberg GR; Liu S; Zukotynski K; Tsakiridis T
Clin Transl Radiat Oncol; 2023 Mar; 39():100583. PubMed ID: 36713978
[TBL] [Abstract][Full Text] [Related]
28. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic performance of
Afshar-Oromieh A; Holland-Letz T; Giesel FL; Kratochwil C; Mier W; Haufe S; Debus N; Eder M; Eisenhut M; Schäfer M; Neels O; Hohenfellner M; Kopka K; Kauczor HU; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1258-1268. PubMed ID: 28497198
[TBL] [Abstract][Full Text] [Related]
30. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
Özülker T; Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
[TBL] [Abstract][Full Text] [Related]
33. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
34. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
Hope TA; Truillet C; Ehman EC; Afshar-Oromieh A; Aggarwal R; Ryan CJ; Carroll PR; Small EJ; Evans MJ
J Nucl Med; 2017 Jan; 58(1):81-84. PubMed ID: 27660139
[TBL] [Abstract][Full Text] [Related]
35. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
36. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
[TBL] [Abstract][Full Text] [Related]
37. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
38. Gene's expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study.
Bauckneht M; Marini C; Cossu V; Campi C; Riondato M; Bruno S; Orengo AM; Vitale F; Carta S; Chiola S; Chiesa S; Miceli A; D'Amico F; Fornarini G; Terrone C; Piana M; Morbelli S; Signori A; Barboro P; Sambuceti G
J Transl Med; 2023 Jan; 21(1):3. PubMed ID: 36600265
[TBL] [Abstract][Full Text] [Related]
39. Impact of
Soeda F; Watabe T; Naka S; Liu Y; Horitsugi G; Neels OC; Kopka K; Tatsumi M; Shimosegawa E; Giesel FL; Hatazawa J
J Nucl Med; 2019 Nov; 60(11):1594-1599. PubMed ID: 30902876
[TBL] [Abstract][Full Text] [Related]
40. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
